Improvements to restriction fragment length polymorphism (RFLP)-based genotyping assays currently used for detection of mutations responsible for bovine ferrochelatase and myophosphorylase deficiencies, and equine hyperkalemic periodic paralysis (HYPP) are described. Reports of sporadic inhibition of restriction enzyme activity suggest a critical factor in RFLP-based genotyping assays should be assurance that restriction enzymes perform to specification with every sample. The RFLP genotyping assays that use either a mismatched recognition sequence in one or both of the oligonucleotides, or incorporate a second native site within the PCR amplicon, provide the mechanism by which efficiency of restriction enzymes can be assessed with every sample. The outcome is confirmation of the activity of the discriminating enzyme regardless of genotype.
The autosomal defects, bovine ferrochelatase deficiency, bovine myophosphorylase deficiency, and equine hyperkalemic periodic paralysis (HYPP), were first recorded in Limousin cattle, Charolais cattle, and Quarter Horses, respectively, in North America. 1, 8, 9 Photosensitivity and resultant cutaneous lesions on the nares and pinnae are the most common clinical presentation associated with ferrochelatase deficiency (protoporphyria). 8 Although it is not life threatening, the condition may reduce productivity, particularly in immature subjects. Bovine myophosphorylase deficiency may be life threatening under extensive management systems, but homozygous mutant animals can survive to breeding age if managed under intensive systems. 2 The predominant clinical manifestation of HYPP is muscular fasciculation that may progress to paralysis, but is not usually fatal. 7, 9 Individual seed-stock producers and some national breed societies have attempted to reduce the prevalence of heterozygotes for genetic defects in bullbreeding herds and equine stud operations to the benefit of commercial breeders. Consequently, transfer of Limousin, Charolais, and Quarter Horse germplasm between national studbook registers may be subject to screening for the respective deficiency.
The 3 defects are caused by single base substitutions in their respective genes. Bovine ferrochelatase deficiency is the result of a GRT transversion at nucleotide 1,250 in exon 11 of the ferrochelatase gene, converting the stop codon to a leucine codon. Translation is terminated when the next in-frame stop codon is reached, resulting in an additional 27 amino acids at the carboxy terminus of the protein. 5 Bovine myophosphorylase deficiency is caused by a CRT transition at nucleotide 1,468 in exon 12 of the myophosphorylase gene, converting an arginine codon at position 490 to tryptophan. 10 Hyperkalemic periodic paralysis is a consequence of a nucleotide 4,248 CRG transversion in exon 23 (the transmembrane domain) of the a subunit of the sodium channel gene. 7 The transversion is predicted to alter a phenylalanine to a leucine codon in the highly conserved region of this subunit. Thus, in the 3 defects, the altered amino acid composition of the gene products results in dysfunctional polypeptides.
Each of the mutations creates or deletes restriction enzyme recognition sites. The nucleotide 1,250 GRT mutation, and a linked nucleotide 1,252 CRA transversion in the bovine ferrochelatase gene create an HpaI recognition site at the 59 end of exon 11 (GenBank accession number L34173). The myophosphorylase nucleotide 1,468 CRT mutation creates a unique StyI recognition site in exon 12 (GenBank accession number S82859). The nucleotide 4,248 CRG transversion in the a-subunit of the sodium channel gene deletes the second of 2 native TaqI sites in exon 23 (GenBank accession number ECU25990). Thus, polymerase chain reaction (PCR) followed by restriction fragment length polymorphism (RFLP) analyses can be used to genotype individuals for these defects. However, inhibition of restriction enzyme activity by illdefined factors in target DNA has the potential to complicate diagnoses of genotype. This is illustrated by the inhibition of DrdI in the assay used to genotype cattle for the acidic a-glucosidase 2454DCA mutation. 3 Mismatch amplification to create a ''quality assurance'' DrdI recognition site in wild-type and mutant amplicons resolved this issue. In that study, primers were designed that incorporate similar ''quality assurance'' recognition sites into amplicons used to genotype for bovine ferrochelatase and myophosphorylase deficiencies. The mismatches were created in positions to maximize the size of the cleaved qualityassurance fragment without compromising fidelity of amplification. A second native TaqI site within the HYPP amplicon provided the required quality-assurance recognition site without the need for mismatch primers.
The ferrochelatase primers (sense 59ACACCTCCAGTC-CAAGGAGCGCTG 39 and antisense 59TTGGCCA-GAGGCTAAGCCGGCACGGAGT TAACC 39) allow amplification of a 234-bp fragment within exon 11. The substitution of GT for TG in the antisense primer creates an HpaI recognition site that cleaves 29 bp from the 39 end of wild-type and mutant amplicons. The HpaI site created by the 1250T and 1252A haplotype is predicted to cleave the residual 205-bp fragment into 94-and 111-bp fragments.
The myophosphorylase primers (sense 59CCAGGAA-GACCCTCATTCCA 39 and antisense 59AATGATCTC-TGCCAGCCAAGG 39) allow amplification of a 166-bp fragment that includes 58 bp at the 39 end of intron 11 and 108 bp into exon 12. The italicized A in place of G in the antisense primer creates a StyI site in wild-type and mutant amplicons, cleaving 19 bp from the 39 end. With the mutant amplicon, the residual 147-bp fragment is further cleaved to yield 120-and 27-bp fragments (predicted band sizes for ''sticky ends'' created by StyI cleavage are presented for the 59 to 39 strand only, to simplify presentation of results).
The HYPP primer pair (sense 59TATGACTTTGTGAC-GAAGCAGGT 39 and antisense 59CCACAATGGAC-AGGATGACAAC 39) allows amplification of a 250-bp fragment within exon 23 of the a-subunit of the equine sodium channel gene. The TaqI cleaves 28 and 32 bp, from the 59 and 39 ends of the wild-type amplicon, respectively, leaving a residual 190-bp fragment. The nucleotide 4,248 CRG transversion deletes the 39TaqI site, resulting in a residual mutant fragment of 222 bp.
For this study, DNA extracts were prepared from 10-ml unclotted blood samples using a saturated salt extraction procedure. 6 In addition, the methods have been validated using high throughput crude DNA extracts from tail hair, 4 blood, and semen (bovine assays only) (data not shown). Crude DNA extracts from unclotted blood were prepared by mixing 100 ml of whole blood with 1 ml of Tris-EDTA, pH 8.0 (TE), followed by centrifugation at 400 3g for 10 seconds. The supernatant was discarded, and the pellet was resuspended in 1 ml of TE before repeating the process for a total of 3 TE washes. After the final wash, the pellet was resuspended in 200 ml of digest buffer (10 mM Tris-HCl, pH 8.3; 50 mM KCl, 1.5 mM MgCl 2 , 0.1 mg of proteinase K/ml, and 0.5% Tween 20) and was heat treated, as described for hair roots. 4 Crude DNA extracts from semen were obtained by mixing 100 ml of commercial semen with 1 ml of purified water before centrifugation at 80 3g for 1 minute. After two 1-ml saline washes by resuspension and centrifugation, the pellet was resuspended in 90 ml of TEN (10 mM Tris-HCl, pH 7.4, 2 mM EDTA, pH 8.0, 400 mM NaCl) buffer and 10 ml of 1 M NaOH, prior to heat treatment at 95uC for 2-15 minutes.
Quantification of DNA was not required with any procedure before PCR analysis, although optimal amplification and digestion was observed with 1:10 dilutions of saturated salt DNA extracts and undiluted crude DNA preparations from hair, blood, and semen.
The PCR analysis was performed in FTS 1 capillary thermocyclers a in a reaction volume of 10 ml. Reagents were 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl 2 , 0.1 M dNTP, 0.75 mM each primer, 0.25 U of Taq polymerase, b and 1 ml of target DNA. After an initial denaturation step at 94uC for 3 minutes, amplification was performed using 35 cycles comprising denaturation for 10 seconds at 94uC, annealing for 15 seconds at 57uC (ferrochelatase)/60uC (myophosphorylase)/55uC (HYPP), extension for 20 seconds at 72uC, and finishing with a single step at 72uC for 2 minutes. Without further processing, the PCR products were incubated directly with the respective restriction enzymes under reaction conditions recommended by the manufacturer. c Cleavage products were separated on 4% agarose gels, and were visualized using ethidium bromide. Lane 6 in panels A and B illustrates the characteristic RFLP when only the mutations are present for ferrochelatase and myophosphorylase deficiencies, respectively. The bands evident after digestion of amplicon derived from the ferrochelatase-and myophosphorylase-deficient subjects are consistent with those predicted, given the nature of the mutations and the presence of the engineered ''quality assurance'' sites. The DNA from a HYPP-affected animal was not available for this study.
The aforedescribed protocols impart a valuable additional level of quality assurance to these PCR/RFLP genotyping assays. This is particularly important to laboratory clients in the context of international trade of bovine and equine germplasm. 
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